연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2024년 | 2023년 | 2022년 | 2021년 | 2020년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 179편 | 173편 | 163편 | 184편 | 135편 |
| 공동 | 147편 | 120편 | 115편 | 136편 | 168편 | |
| 합계 | 326편 | 293편 | 278편 | 320편 | 303편 | |
1867. Implication of Tumor Location for Lymph Node Metastasis in Maxillary Sinus Carcinoma: Indications for Elective Neck Treatment
Jeon SH, Han DH, Won TB, Keam B, Kim JH, Wu HG
J Oral Maxillofac Surg. 2016 Oct 13. pii: S0278-2391(16)30946-6. doi: 10.1016/j.joms.2016.10.004
Link
1866. Prospective investigation and literature review of tolerance dose on salivary glands using quantitative salivary gland scintigraphy in the intensity-modulated radiotherapy era
Lee SW, Kang KW, Wu HG
Head Neck. 2016 Apr;38 Suppl 1:E1746-55
Link
1865. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
Cho KM, Park H, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ.
Oncotarget. 2016 Nov 30. doi: 10.18632/oncotarget.13731. [Epub ahead of print]
Link
1864. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.
Ha H, Nam AR, Bang JH, Park JE, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ, Oh DY.
Oncotarget. 2016 Nov 22;7(47):76604-76612. doi: 10.18632/oncotarget.12810.
Link
1863. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
An E, Ock CY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci DV, Oh DY, Bang YJ.
Ann Oncol. 2016 Sep 29. pii: mdw442. doi: 10.1093/annonc/mdw442. [Epub ahead of print]
Link
1862. Therapeutic implication of HER2 in advanced biliary tract cancer.
Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Oncotarget. 2016 Sep 6;7(36):58007-58021. doi: 10.18632/oncotarget.11157.
Link
1861. Src as a Therapeutic Target in Biliary Tract Cancer.
Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Lee KH, Kim TY, Han SW, Im SA, Kim TY, Oh DY, Bang YJ.
Mol Cancer Ther. 2016 Jul;15(7):1515-24. doi: 10.1158/1535-7163.MCT-16-0013. Epub 2016 Apr 22.
Link
1860. Prognostic implication of antitumor immunity measured by the neutrophil-lymphocyte ratio and serum cytokines and angiogenic factors in gastric cancer.
Ock CY, Nam AR, Lee J, Bang JH, Lee KH, Han SW, Kim TY, Im SA, Kim TY, Bang YJ, Oh DY.
Gastric Cancer. 2016 May 5. [Epub ahead of print]
Link
1859. Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer.
Ha HR, Oh DY, Kim TY, Lee K, Kim K, Lee KH, Han SW, Chie EK, Jang JY, Im SA, Kim TY, Kim SW, Bang YJ.
PLoS One. 2016 Mar 14;11(3):e0151406. doi: 10.1371/journal.pone.0151406. eCollection 2016.
Link
1858. More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity.
Choi Y, Oh DY, Park H, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ.
PLoS One. 2016 Jan 4;11(1):e0145692. doi: 10.1371/journal.pone.0145692. eCollection 2016.
Link